October 2019
Preliminary Terms No. 2,643
Registration Statement Nos. 333-221595;
333-221595-01
Dated October 2, 2019
Filed pursuant to Rule 433
Morgan Stanley Finance LLC
Structured
Investments
Opportunities in U.S. Equities
Contingent Income Buffered Auto-Callable Securities
due October 31, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst
Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
Fully and Unconditionally
Guaranteed by Morgan Stanley
Principal at Risk Securities
The securities
offered are unsecured obligations of Morgan Stanley Finance LLC (“MSFL”) and are fully and unconditionally guaranteed
by Morgan Stanley. The securities have the terms described in the accompanying product supplement, index supplement and prospectus,
as supplemented or modified by this document. The securities do not provide for the regular payment of interest and provide a minimum
payment at maturity of only 15% of the stated principal amount. Instead, the securities will pay a contingent monthly coupon (plus
any previously unpaid contingent monthly coupons from prior observation dates) but only if the determination closing price
of each of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund,
which we refer to as the underlying shares, is at or above 80%
of its respective initial share price, which we refer to as the coupon barrier level, on
the related observation date. If, however, the determination closing price of either of the underlying shares is less than
its respective coupon barrier level on any observation date, we will pay no interest for the related monthly period. Beginning
after one-and-a-half years, the securities will be automatically redeemed if the determination closing price of each of
the underlying shares is greater than or equal to its respective initial share price on
any monthly redemption determination date for the early redemption payment equal to the sum of the stated principal amount plus
the related contingent monthly coupon and any previously unpaid contingent monthly coupons from prior observation dates.
No further payments will be made on the securities once they have been redeemed. At maturity, if the securities have not
previously been redeemed and the final share price of each of the underlying shares is greater than or equal to 85% of its
respective initial share price, meaning that neither of the underlying shares has declined by an amount greater than the
buffer amount of 15%, the payment at maturity will be the stated principal amount and the related contingent monthly coupon and
any previously unpaid contingent monthly coupons from prior observation dates. However, if the final share price of either of
the underlying shares is less than 85% of its respective initial share price, meaning that either of the underlying
shares has declined by an amount greater than the buffer amount of 15%, investors will lose 1% for every 1% decline in the final
share price of the worst performing underlying shares from its initial share price beyond the buffer amount of 15%. Accordingly,
investors in the securities must be willing to accept the risk of losing up to 85% of their initial investment and also the
risk of not receiving any contingent monthly coupons throughout the 5-year term of the securities. These long-dated securities
are for investors who are willing to risk their principal and seek an opportunity to earn interest at a potentially above-market
rate in exchange for the risk of receiving no monthly interest over the entire 5-year term and in exchange for the possibility
of an automatic early redemption prior to maturity. Because the payment of contingent monthly coupons is based on the worst performing
of the underlying shares, the fact that the securities are linked to two underlying shares does not provide any asset diversification
benefits and instead means that a decline in the price of either of the underlying shares below the relevant coupon barrier level
will result in no contingent monthly coupons, even if the other underlying shares closes at or above its respective coupon barrier
level. Because all payments on the securities are based on the worst performing of the underlying shares, a decline of either of
the underlying shares by an amount greater than the buffer amount as of the final observation date will result in a loss of your
investment, even if the other underlying shares has appreciated or has not declined as much. Investors will not participate in
any appreciation of either of the underlying shares. The securities are notes issued as part of MSFL’s Series A Global Medium-Term
Notes program.
All payments are subject to our credit risk. If we default on
our obligations, you could lose some or all of your investment. These securities are not secured obligations and you will not have
any security interest in, or otherwise have any access to, any underlying reference asset or assets.
SUMMARY TERMS
|
Issuer:
|
Morgan Stanley Finance LLC
|
Guarantor:
|
Morgan Stanley
|
Underlying shares:
|
SPDR® S&P® Biotech ETF (the “XBI Shares”) and Energy Select Sector SPDR® Fund (the “XLE Shares”)
|
Aggregate principal amount:
|
$
|
Stated principal amount:
|
$1,000 per security
|
Issue price:
|
$1,000 per security
|
Pricing date:
|
October 28, 2019
|
Original issue date:
|
October 31, 2019 (2 business days after the pricing date)
|
Maturity date:
|
October 31, 2024
|
Early redemption:
|
The securities are not subject to automatic early redemption until
approximately one-and-a-half years after the original issue date.
Following this initial 1.5-year non-call period, if, on any redemption
determination date, beginning on April 28, 2021, the determination closing price of each of the underlying shares is greater
than or equal to its respective initial share price, the securities will be automatically redeemed for an early redemption payment
on the related early redemption date. No further payments will be made on the securities once they have been redeemed.
The securities will not be redeemed early on any early redemption
date if the determination closing price of either of the underlying shares is below its respective initial share price on the related
redemption determination date.
|
Early redemption payment:
|
The early redemption payment will be an amount equal to (i) the stated principal amount for each security you hold plus (ii) the contingent monthly coupon with respect to the related observation date and any previously unpaid contingent monthly coupons from prior observation dates.
|
Determination closing price:
|
With respect to each of the underlying shares, the closing price of such underlying shares on any redemption determination date or observation date (other than the final observation date), times the adjustment factor on such redemption determination date or observation date, as applicable
|
Redemption determination dates:
|
Monthly, as set forth under “Observation Dates, Redemption Determination Dates, Coupon Payment Dates and Early Redemption Dates” below, subject to postponement for non-trading days and certain market disruption events.
|
Early redemption dates:
|
Starting on May 3, 2021 (approximately one-and-a-half years after the original issue date), monthly. See “Observation Dates, Redemption Determination Dates, Coupon Payment Dates and Early Redemption Dates” below. If any such day is not a business day, that early redemption payment, if payable, will be made on the next succeeding business day and no adjustment will be made to any early redemption payment made on that succeeding business day.
|
Contingent monthly coupon:
|
A contingent monthly coupon at an annual rate of 8.00 to 10.00%
(corresponding to approximately $6.667 to $8.333 per month per security, to be determined on the pricing date) will be paid on
the securities on each coupon payment date but only if the determination closing price of each of the underlying
shares is at or above its respective coupon barrier level on the related observation date.
If the contingent monthly coupon is not paid on any coupon payment
date (because the determination closing price of either of the underlying shares on any observation date is less than the respective
coupon barrier level), such unpaid contingent monthly coupon will be paid on a later coupon payment date but only if the determination
closing price of each of the underlying shares on such later observation date is greater than or equal to the respective coupon
barrier level;
provided, however,
in the case of any such payment of a previously unpaid contingent monthly coupon, that no additional interest shall accrue or be
payable in respect of such unpaid contingent monthly coupon from and after the end of the original interest period for such unpaid
contingent monthly coupon. You will not receive such unpaid contingent monthly coupons if the determination closing price of either
of the underlying shares is less than the respective coupon barrier level on each subsequent observation date.
If, on any observation date, the determination closing price of
either of the underlying shares is less than its respective coupon barrier level, no contingent monthly coupon will be paid with
respect to that observation date. It is possible that one or both of the underlying shares will remain below their respective coupon
barrier levels for extended periods of time or even throughout the entire 5-year term of the securities so that you will receive
few or no contingent monthly coupons.
|
Coupon barrier level:
|
With respect to the XBI Shares, $ , which is equal to 80% of its
initial share price
With respect to the XLE Shares, $ , which is equal to 80% of its
initial share price
|
Buffer amount:
|
With respect to each of the underlying shares, 15%. As a result of
the buffer amount of 15%, the price at or above which each of the underlying shares must close on the final observation date so
that investors do not suffer a loss on their initial investment in the securities is as follows:
With respect to the XBI Shares, $ , which is equal to 85% of its
initial share price
With respect to the XLE Shares, $ , which is equal to 85% of its
initial share price
|
Payment at maturity:
|
If the securities are not redeemed
prior to maturity, investors will receive a payment at maturity determined as follows:
· If the final share price of each of the underlying shares is greater than or equal to 85% of its respective initial share
price, meaning that neither of the underlying shares has decreased by an amount greater than the buffer amount of 15% from its
respective initial share price: the stated principal amount and the contingent monthly coupon with respect to the final observation
date and any previously unpaid contingent monthly coupons with respect to the prior observation dates
· If the final share price of either of the underlying shares is less than 85% of its respective initial share price, meaning
that either of the underlying shares has decreased by an amount greater than the buffer amount of 15% from its respective
initial share price:
$1,000 + [$1,000 x (share percent
change of the worst performing underlying shares + 15%)]
If the final share price of each of the underlying
shares is greater than or equal to its respective coupon barrier level, investors will receive the contingent monthly coupon with
respect to the final observation date and any previously unpaid contingent monthly coupons from prior observation dates.
Under these circumstances, the payment at maturity will be less
than the stated principal amount of $1,000. However, under no circumstances will the securities pay less than the minimum payment
at maturity of $150 per security.
|
|
Terms continued on the following page
|
Agent:
|
Morgan Stanley & Co. LLC (“MS & Co.”), an affiliate of MSFL and a wholly owned subsidiary of Morgan Stanley. See “Supplemental information regarding plan of distribution; conflicts of interest.”
|
Estimated value on the pricing date:
|
Approximately $907.10 per security, or within $30.00 of that estimate. See “Investment Summary” beginning on page 4.
|
Commissions and issue price:
|
Price to public
|
Agent’s commissions(1)
|
Proceeds to us(2)
|
Per security
|
$1,000
|
$
|
$
|
Total
|
$
|
$
|
$
|
|
(1)
|
Selected dealers
and their financial advisors will collectively receive from the agent, MS & Co.,
a fixed sales commission of $ for each security they sell. See “Supplemental information
regarding plan of distribution; conflicts of interest.” For additional information,
see “Plan of Distribution (Conflicts of Interest)” in the accompanying product
supplement.
|
|
(2)
|
See “Use
of proceeds and hedging” on page 28.
|
The securities involve risks not associated with an investment
in ordinary debt securities. See “Risk Factors” beginning on page 12.
The Securities and Exchange Commission and state securities regulators
have not approved or disapproved these securities, or determined if this document or the accompanying product supplement, index
supplement and prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The securities are not deposits or savings accounts and are not
insured by the Federal Deposit Insurance Corporation or any other governmental agency or instrumentality, nor are they obligations
of, or guaranteed by, a bank.
You should read this document together with the related product
supplement, index supplement and prospectus, each of which can be accessed via the hyperlinks below. Please also see “Additional
Terms of the Securities” and “Additional Information About the Securities” at the end of this document.
As used in this document, “we,” “us” and
“our” refer to Morgan Stanley or MSFL, or Morgan Stanley and MSFL collectively, as the context requires.
Product Supplement for Auto-Callable Securities dated November 16, 2017 Index Supplement dated November 16, 2017
Prospectus dated November 16, 2017
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
Terms continued from previous page:
|
Initial share price:
|
With respect to the XBI Shares, $ , which is its closing price on
the pricing date
With respect to the XLE Shares, $ , which is its closing price on
the pricing date
|
Coupon payment dates:
|
Monthly, as set forth under “Observation Dates, Redemption Determination Dates, Coupon Payment Dates and Early Redemption Dates” below. If any such day is not a business day, that coupon payment will be made on the next succeeding business day and no adjustment will be made to any coupon payment made on that succeeding business day; provided that the contingent monthly coupon, if any, with respect to the final observation date shall be paid on the maturity date.
|
Observation dates:
|
Monthly, as set forth under “Observation Dates, Redemption Determination Dates, Coupon Payment Dates and Early Redemption Dates” below, subject to postponement for non-trading days and certain market disruption events. We also refer to October 28, 2024, which is the third scheduled business day preceding the scheduled maturity date, as the final observation date.
|
Final share price:
|
With respect to each of the underlying shares, the closing price of such underlying shares on the final observation date times the adjustment factor on such date
|
Minimum payment at maturity:
|
$150 per security (15% of the stated principal amount)
|
Adjustment factor:
|
With respect to each of the underlying shares, 1.0, subject to adjustment in the event of certain events affecting such underlying shares
|
Worst performing underlying shares:
|
The underlying shares with the larger percentage decrease from the respective initial share price to the respective final share price
|
Share percent change:
|
With respect to each of the underlying shares: (final share price – initial share price) / initial share price
|
CUSIP / ISIN:
|
61769HA39 / US61769HA399
|
Listing:
|
The securities will not be listed on any securities exchange.
|
Observation
Dates, Redemption Determination Dates, Coupon Payment Dates and Early Redemption Dates
Observation Dates / Redemption Determination Dates
|
Coupon Payment Dates / Early Redemption Dates
|
11/29/2019*
|
12/4/2019*
|
12/30/2019*
|
1/3/2020*
|
1/28/2020*
|
1/31/2020*
|
2/28/2020*
|
3/4/2020*
|
3/30/2020*
|
4/2/2020*
|
4/28/2020*
|
5/1/2020*
|
5/28/2020*
|
6/2/2020*
|
6/29/2020*
|
7/2/2020*
|
7/28/2020*
|
7/31/2020*
|
8/28/2020*
|
9/2/2020*
|
9/28/2020*
|
10/1/2020*
|
10/28/2020*
|
11/2/2020*
|
11/30/2020*
|
12/3/2020*
|
12/28/2020*
|
12/31/2020*
|
1/28/2021*
|
2/2/2021*
|
2/26/2021*
|
3/3/2021*
|
3/29/2021*
|
4/1/2021*
|
4/28/2021
|
5/3/2021
|
5/28/2021
|
6/3/2021
|
6/28/2021
|
7/1/2021
|
7/28/2021
|
8/2/2021
|
8/30/2021
|
9/2/2021
|
9/28/2021
|
10/1/2021
|
10/28/2021
|
11/2/2021
|
11/29/2021
|
12/2/2021
|
12/28/2021
|
12/31/2021
|
1/28/2022
|
2/2/2022
|
2/28/2022
|
3/3/2022
|
3/28/2022
|
3/31/2022
|
4/28/2022
|
5/3/2022
|
5/31/2022
|
6/3/2022
|
6/28/2022
|
7/1/2022
|
7/28/2022
|
8/2/2022
|
8/29/2022
|
9/1/2022
|
9/28/2022
|
10/3/2022
|
10/28/2022
|
11/2/2022
|
11/28/2022
|
12/1/2022
|
12/28/2022
|
1/3/2023
|
1/30/2023
|
2/2/2023
|
2/28/2023
|
3/3/2023
|
3/28/2023
|
3/31/2023
|
4/28/2023
|
5/3/2023
|
5/30/2023
|
6/2/2023
|
6/28/2023
|
7/3/2023
|
7/28/2023
|
8/2/2023
|
8/28/2023
|
8/31/2023
|
9/28/2023
|
10/3/2023
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
Observation Dates / Redemption Determination Dates
|
Coupon Payment Dates / Early Redemption Dates
|
10/30/2023
|
11/2/2023
|
11/28/2023
|
12/1/2023
|
12/28/2023
|
1/3/2024
|
1/29/2024
|
2/1/2024
|
2/28/2024
|
3/4/2024
|
3/28/2024
|
4/2/2024
|
4/29/2024
|
5/2/2024
|
5/28/2024
|
5/31/2024
|
6/28/2024
|
7/3/2024
|
7/29/2024
|
8/1/2024
|
8/28/2024
|
9/3/2024
|
9/30/2024
|
10/3/2024
|
10/28/2024 (final observation date)
|
10/31/2024 (maturity date)
|
* The securities are not subject to automatic early redemption
until the eighteenth coupon payment date, which is May 3, 2021.
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
Investment Summary
Contingent Income Buffered Auto-Callable Securities
Principal at Risk Securities
Contingent Income Buffered Auto-Callable Securities due October
31, 2024, With 1.5-year Initial Non-Call Period All Payments on the Securities Based on the Worst Performing of the SPDR®
S&P® Biotech ETF and the Energy Select Sector SPDR® Fund (the “securities”) do not
provide for the regular payment of interest. Instead, the securities will pay a contingent monthly coupon (plus any previously
unpaid contingent monthly coupons from prior observation dates) but only if the determination closing price of each of
the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund, which
we refer to as the underlying shares, is at or above 80% of its respective initial share price, which we refer to as the
coupon barrier level, on the related observation date. If, however, the determination closing price of either of the underlying
shares is less than its respective coupon barrier level on any observation date, we will pay no interest for the related monthly
period. Beginning after one-and-a-half years, the securities will be automatically redeemed if the determination closing price
of each of the underlying shares is greater than or equal to its respective initial share price on any monthly redemption
determination date for the early redemption payment equal to the sum of the stated principal amount plus the related contingent
monthly coupon and any previously unpaid contingent monthly coupons from prior observation dates. No further payments will be made
on the securities once they have been redeemed. At maturity, if the securities have not previously been redeemed and the final
share price of each of the underlying shares is greater than or equal to 85% of its respective initial share price, meaning
that neither of the underlying shares has declined by an amount greater than the buffer amount of 15%, the payment at maturity
will be the stated principal amount and the related contingent monthly coupon and any previously unpaid contingent monthly coupons
from prior observation dates. However, if the final share price of either of the underlying shares is less than 85%
of its respective initial share price, meaning that either of the underlying shares has declined by an amount greater than
the buffer amount of 15%, investors will lose 1% for every 1% decline in the final share price of the worst performing underlying
shares from its initial share price beyond the buffer amount of 15%. Accordingly, investors in the securities must be
willing to accept the risk of losing up to 85% of their initial investment and also the risk of not receiving any contingent monthly
coupons throughout the 5-year term of the securities. Investors will not participate in any appreciation in the price of either
of the underlying shares.
Maturity:
|
5 years
|
Contingent monthly coupon:
|
A contingent monthly coupon at an annual rate of 8.00
to 10.00% (corresponding to at least approximately $6.667 to $8.333 per month per security, to be determined on the pricing date)
will be paid on the securities on each coupon payment date but only if the determination closing price of each of the
underlying shares is at or above its respective coupon barrier level on the related observation date.
If the contingent monthly coupon is not paid on any coupon
payment date (because the determination closing price of either of the underlying shares on any observation date is less than the
respective coupon barrier level), such unpaid contingent monthly coupon will be paid on a later coupon payment date but only if
the determination closing price of each of the underlying shares on such later observation date is greater than or equal to the
respective coupon barrier level;
provided, however,
in the case of any such payment of a previously unpaid contingent monthly coupon, that no additional interest shall accrue or be
payable in respect of such unpaid contingent monthly coupon from and after the end of the original interest period for such unpaid
contingent monthly coupon. You will not receive such unpaid contingent monthly coupons if the determinaton closing price of either
of the underlying shares is less than the respective coupon barrier level on each subsequent observation date.
If, on any observation date, the determination closing
price of either of the underlying shares is less than its respective coupon barrier level, no contingent monthly coupon will be
paid with respect to that observation date. It is possible that one or both of the underlying shares will remain below their respective
coupon barrier levels for extended periods of time or even throughout the entire 5-year term of the securities so that you will
receive few or no contingent monthly coupons.
|
Automatic early redemption monthly starting after one-
|
The securities are not subject to automatic early redemption until approximately one-and-a-half years after the original issue date. Following this initial 1.5-year non-call period, if the determination closing price of each of the underlying shares is greater than or equal to its
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
and-a-half years:
|
respective initial share price on any monthly redemption determination date, beginning on April 28, 2021, the securities will be automatically redeemed for an early redemption payment equal to the stated principal amount plus the contingent monthly coupon with respect to the related observation date. No further payments will be made on the securities once they have been redeemed.
|
Payment at maturity:
|
If the securities have not previously been redeemed and the final
share price of each of the underlying shares is greater than or equal to 85% of its respective initial share price,
meaning that neither of the underlying shares has declined by an amount greater than the buffer amount of 15%, the payment
at maturity will be the stated principal amount and the related contingent monthly coupon and any previously unpaid contingent
quarterly coupons from prior observation dates.
If the final share price of either of the underlying shares
is less than 85% of its respective initial share price, meaning that either of the underlying shares has declined
by an amount greater than the buffer amount of 15%, investors will lose 1% for every 1% decline in the final share price of the
worst performing underlying shares from its initial share price beyond the buffer amount of 15%. If the final share price of each
of the underlying shares is greater than or equal to its respective coupon barrier level, investors will receive the contingent
monthly coupon with respect to the final observation date and any previously unpaid contingent monthly coupons from prior observation
dates. Under these circumstances, the payment at maturity will be less than the stated principal amount of the securities. However,
under no circumstances will the securities pay less than the minimum payment at maturity of $150 per security. Accordingly,
investors in the securities must be willing to accept the risk of losing up to 85% of their initial investment.
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
The original issue price of each security is
$1,000. This price includes costs associated with issuing, selling, structuring and hedging the securities, which are borne by
you, and, consequently, the estimated value of the securities on the pricing date will be less than $1,000. We estimate that the
value of each security on the pricing date will be approximately $907.10, or within $30.00 of that estimate. Our estimate of the
value of the securities as determined on the pricing date will be set forth in the final pricing supplement.
What goes into the estimated value on the pricing date?
In valuing the securities on the pricing date,
we take into account that the securities comprise both a debt component and a performance-based component linked to the underlying
shares. The estimated value of the securities is determined using our own pricing and valuation models, market inputs and assumptions
relating to the underlying shares, instruments based on the underlying shares, volatility and other factors including current and
expected interest rates, as well as an interest rate related to our secondary market credit spread, which is the implied interest
rate at which our conventional fixed rate debt trades in the secondary market.
What determines the economic terms of the securities?
In determining the economic terms of the securities,
including the contingent monthly coupon rate, the coupon barrier levels and the buffer amount, we use an internal funding rate,
which is likely to be lower than our secondary market credit spreads and therefore advantageous to us. If the issuing, selling,
structuring and hedging costs borne by you were lower or if the internal funding rate were higher, one or more terms of the securities
would be more favorable to you.
What is the relationship between the estimated value on the
pricing date and the secondary market price of the securities?
The price at which MS & Co. purchases the
securities in the secondary market, absent changes in market conditions, including those related to the underlying shares, may
vary from, and be lower than, the estimated value on the pricing date, because the secondary market price takes into account our
secondary market credit spread as well as the bid-offer spread that MS & Co. would charge in a secondary market transaction
of this type and other factors. However, because the costs associated with issuing, selling, structuring and hedging the securities
are not fully deducted upon issuance, for a period of up to 6 months following the issue date, to the extent that MS & Co.
may buy or sell the securities in the secondary market, absent changes in market conditions, including those related to the underlying
shares, and to our secondary market credit spreads, it would do so based on values higher than the estimated value. We expect that
those higher values will also be reflected in your brokerage account statements.
MS & Co. may, but is not obligated to, make a market in the
securities and, if it once chooses to make a market, may cease doing so at any time.
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
Key Investment Rationale
The securities do not provide for the regular payment of interest.
Instead, the securities will pay a contingent monthly coupon (plus any previously unpaid contingent monthly coupons from prior
observation dates) but only if the determination closing price of each of the underlying shares is at or above
its respective coupon barrier level on the related observation date. The securities have been designed for investors who are
willing to forgo market floating interest rates and risk the loss of principal and accept the risk of receiving few or no coupon
payments for the entire 5-year term of the securities in exchange for an opportunity to earn interest at a potentially above-market
rate if both of the underlying shares close at or above their respective coupon barrier levels on each monthly observation date,
unless the securities are redeemed early. The following scenarios are for illustration purposes only to demonstrate how the coupon
and the payment at maturity (if the securities have not previously been redeemed) are calculated, and do not attempt to demonstrate
every situation that may occur. Accordingly, the securities may or may not be redeemed, the contingent monthly coupon may be payable
in none of, or some but not all of, the monthly periods during the 5-year term of the securities, and the payment at maturity may
be up to 85% less than the stated principal amount of the securities.
Scenario 1: The securities are redeemed prior to maturity
|
This scenario assumes that, prior to early redemption, each of
the underlying shares closes at or above its respective coupon barrier level on some monthly observation dates, but one or both
of the underlying shares close below the coupon barrier level(s) on the others. Investors receive the contingent monthly coupon
for the monthly periods for which the determination closing price of each of the underlying shares is at or above its respective
coupon barrier level on the related observation date, but not for the monthly periods for which the determination closing price
of either of the underlying shares is below the respective coupon barrier level(s) on the related observation date.
Beginning after one-and-a-half years, when each of the underlying
shares closes at or above its respective initial share price on a monthly redemption determination date, the securities will be
automatically redeemed for the stated principal amount plus the contingent monthly coupon with respect to the related observation
date and any previously unpaid contingent monthly coupons with respect to any prior observation dates.
|
Scenario 2: The securities are not redeemed prior to maturity, and investors receive principal back at maturity
|
This scenario assumes that each of the underlying shares closes at or above its respective coupon barrier level on some monthly observation dates, but one or both of the underlying shares close below the respective coupon barrier level(s) on the others, and at least one of the underlying shares closes below its initial share price on every monthly redemption determination date. Consequently, the securities are not redeemed early, and investors receive the contingent monthly coupon for the monthly periods for which the determination closing price of each of the underlying shares is at or above its respective coupon barrier level on the related observation date, but not for the monthly periods for which the determination closing price of one or both of the underlying shares is below the respective coupon barrier level(s) on the related observation date. On the final observation date, each of the underlying shares closes at or above 85% of its respective initial share price, meaning that neither of the underlying shares has declined by an amount greater than the buffer amount of 15%. At maturity investors will receive the stated principal amount and the related contingent monthly coupon and any previously unpaid contingent monthly coupons with respect to any prior observation dates.
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
Scenario 3: The securities are not redeemed prior to maturity, and investors suffer a loss of principal at maturity
|
This scenario assumes that each of the underlying shares closes at or above its respective coupon barrier level on some monthly observation dates, but one or both of the underlying shares close below the respective coupon barrier level(s) on the others, and at least one of the underlying shares closes below its initial share price on every monthly redemption determination date. Consequently, the securities are not redeemed early, and investors receive the contingent monthly coupon for the monthly periods for which the determination closing price of each of the underlying shares is greater than or equal to its respective coupon barrier level on the related observation date, but not for the monthly periods for which the determination closing price of one or both of the underlying shares is below the respective coupon barrier level(s) on the related observation date. On the final observation date, at least one of the underlying shares closes below 85% of its respective initial share price, meaning that such underlying shares has declined by an amount greater than the buffer amount of 15%. At maturity, investors will lose 1% for every 1% decline in the final share price of the worst performing underlying shares from its initial share price beyond the buffer amount of 15%. If the final share price of each of the underlying shares is greater than or equal to its respective coupon barrier level, investors will receive the contingent monthly coupon with respect to the final observation date and any previously unpaid contingent monthly coupons from prior observation dates. Under these circumstances, the payment at maturity will be less than the stated principal amount. Investors may lose up to 85% of their investment in the securities.
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
Hypothetical Examples
The following hypothetical examples illustrate how to determine
whether a contingent monthly coupon is paid with respect to an observation date and how to calculate the payment at maturity, assuming
the securities are not redeemed prior to maturity. The following examples are for illustrative purposes only. Whether you receive
a contingent monthly coupon will be determined by reference to the determination closing price of each of the underlying shares
on each monthly observation date, and the amount you will receive at maturity will be determined by reference to the final share
price of each of the underlying shares on the final observation date. The actual initial share price and coupon barrier level for
each of the underlying shares will be determined on the pricing date. All payments on the securities are subject to our credit
risk. The below examples are based on the following terms:
Hypothetical Contingent Monthly Coupon:
|
9.00% per annum (corresponding to approximately $7.50 per month per
security, the midpoint of the specified range)1
With respect to each coupon payment date, a contingent monthly
coupon plus any previously unpaid contingent monthly coupons with respect to any prior observation dates is paid but only if the
determination closing price of each of the underlying shares is at or above its respective coupon barrier level on the related
observation date.
|
Payment at Maturity (if the securities are not redeemed prior to maturity):
|
If the final share price of each of the underlying shares
is greater than or equal to 85% of its respective initial share price: the stated principal amount and the contingent monthly
coupon with respect to the final observation date and any previously unpaid contingent monthly coupons with respect to the prior
observation dates.
If the final share price of either of the underlying shares
is less than 85% of its respective initial share price:
$1,000 + [$1,000 x (share percent change of the worst
performing underlying shares + 15%)]
If the final share price of each of the underlying shares is greater
than or equal to its
respective coupon barrier level, investors will receive the contingent
monthly coupon with
respect to the final observation date and any previously unpaid contingent
monthly coupons from prior observation dates.
|
Stated Principal Amount:
|
$1,000
|
Minimum Payment at Maturity:
|
$150 per security
|
Hypothetical Initial Share Price:
|
With respect to the XBI Shares: $80.00
With respect to the XLE Shares: $60.00
|
Hypothetical Coupon Barrier Level:
|
With respect to the XBI Shares: $64.00, which is 80% of its hypothetical
initial share price
With respect to the XLE Shares: $48.00, which is 80% of its hypothetical
initial share price
|
Buffer Amount:
|
With respect to each of the underlying shares: 15%
|
1 The actual contingent monthly
coupon will be an amount determined by the calculation agent based on the actual contingent monthly coupon and the number of days
in the applicable payment period, calculated on a 30/360 day-count basis. The hypothetical contingent monthly coupon rate of $7.50
is used in these examples for ease of analysis.
How to determine whether a
contingent monthly coupon is payable with respect to an observation date:
|
Determination Closing Price
|
Hypothetical Contingent Monthly Coupon
|
|
XBI Shares
|
XLE Shares
|
|
Hypothetical Observation Date 1
|
$85.00 (at or above its coupon barrier level)
|
$65.00 (at or above its coupon barrier level)
|
$7.50
|
Hypothetical Observation Date 2
|
$73.00 (at or above its coupon barrier level)
|
$35.50 (below its coupon barrier level)
|
$0
|
Hypothetical Observation Date 3
|
$59.00 (below its coupon barrier level)
|
$55.00 (at or above its coupon barrier level)
|
$0
|
Hypothetical Observation Date 4
|
$74.50 (at or above its coupon barrier level)
|
$65.00 (at or above its coupon barrier level)
|
$7.50 + $7.50 + $7.50 = $22.50
|
Hypothetical Observation Date 5
|
$58.00 (below its coupon barrier level)
|
$45.00 (below its coupon barrier level)
|
$0
|
On hypothetical observation date 1, each of the underlying shares
closes at or above its respective coupon barrier level. Therefore, a hypothetical contingent monthly coupon of $7.50 is paid on
the relevant coupon payment date.
On each of hypothetical observation dates 2 and 3, one of the
underlying shares closes at or above its respective coupon barrier level but the other underlying shares closes below its respective
coupon barrier level. Therefore, no contingent monthly coupon is paid on the relevant coupon payment date.
On hypothetical observation date 4, each of the underlying shares
closes at or above its respective coupon barrier level. Therefore, investors receive the hypothetical contingent monthly coupon
with respect to the fourth observation date as well as the previously unpaid contingent monthly coupons with respect to the second
and third observation dates.
On hypothetical observation date 5, each of the underlying shares
closes below its respective coupon barrier level and accordingly no contingent monthly coupon is paid on the relevant coupon payment
date.
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
You will not receive a contingent monthly coupon on any coupon
payment date if the determination closing price of either of the underlying shares is below its respective coupon barrier level
on the related observation date.
How to calculate the payment at maturity:
In the following examples, one or both of the underlying shares
close below the respective initial share price(s) on each redemption determination date, and, consequently, the securities are
not automatically redeemed prior to, and remain outstanding until, maturity.
|
Final Share Price
|
Payment at Maturity
|
|
XBI Shares
|
XLE Shares
|
|
Example 1:
|
$95.00 (at or above 85% of initial share price)
|
$57.50 (at or above 85% of initial share price)
|
the stated principal amount and the contingent monthly coupon with respect to the final observation date and any previously unpaid contingent monthly coupons from prior observation dates
|
Example 2:
|
$20.00 (below 85% of initial share price)
|
$55.00 (at or above 85% of initial share price)
|
$1,000 + [$1,000 x (share percent change of the worst performing underlying shares + 15%)]
= $1,000 + [$1,000 x (-75% + 15%)]
= $1,000 + ($1,000 x -60.00%) = $400
|
Example 3:
|
$65.60 (below 85% of initial share price but at or above 80% of the initial share price)
|
$50.40 (below 85% of initial share price but at or above 80% of the initial share price)
|
$1,000 + [$1,000 x (share percent change of the worst performing underlying shares + 15%)]
= $1,000 + [$1,000 x (-23% + 15%)]
= $1,000 + ($1,000 x -8.00%) = $920 + contingent monthly coupon with respect to the final observation date + any previously unpaid contingent monthly coupons from prior observation dates
|
Example 4:
|
$55.00 (below 85% of initial share price)
|
$9.00 (below 85% of initial share price)
|
$1,000 + [$1,000 x (share percent change of the worst performing underlying shares + 15%)]
= $1,000 + [$1,000 x (-85% + 15%)]
= $1,000 + ($1,000 x -70.00%) = $300
|
In example 1, the final share prices of each of the underlying
shares is at or above 85% of its initial share price. Therefore, investors receive at maturity the stated principal amount of the
securities and the hypothetical contingent monthly coupon with respect to the final observation date and any previously unpaid
contingent monthly coupons from prior observation dates. However, investors do not participate in any appreciation of either of
the underlying shares.
In example 2, the final share price of one of the underlying
shares is at or above 85% of its initial share price, but the final share price of the other underlying shares is below 85% of
its initial share price. Therefore, investors are exposed to the downside performance of the XBI Shares, which are the worst performing
underlying shares in this example, and investors lose 1% of principal for every 1% decline in the final share price of the XBI
Shares from its initial share price beyond the buffer amount of 15%. The payment at maturity in this example is equal to $400 per
security. Investors do not receive the contingent monthly coupon for the final observation date.
In example 3, the final share price of each of the underlying
shares is below 85% of its initial share price. Therefore, investors are exposed to the downside performance of the XBI Shares,
which are the worst performing underlying shares in this example, and investors lose 1% of principal for every 1% decline in the
final share price of the XBI Shares from its initial share price beyond the buffer amount of 15%. However, because the final share
price of each of the underlying shares is greater than or equal to its respective coupon barrier level, investors receive the contingent
monthly coupon for the final observation date and any previously unpaid contingent monthly coupons from prior observation dates.
In example 4, the final share prices of both of the underlying
shares are below 85% of their initial share prices. Therefore, investors are exposed to the downside performance of the XLE Shares,
which are the worst performing underlying shares in this example, and investors lose 1% of principal for every 1% decline in the
final share price of the XLE Shares from its initial share price beyond the buffer amount of 15%. The payment at maturity in this
example is equal to $300 per security. Because the final share price of one or both of the underlying shares is below its respective
coupon barrier level, investors do not receive the contingent monthly coupon for the final observation date.
If the final share price of EITHER of the underlying shares
is below 85% of its initial share price, you will be exposed to the downside performance of the worst performing underlying shares
at maturity, and your payment at maturity will be less than
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
the stated principal amount per security. Under these circumstances,
you will lose some, and up to 85%, of your investment in the securities.
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
Risk Factors
The
following is a list of certain key risk factors for investors in the securities. For further discussion of these and other risks,
you should read the section entitled “Risk Factors” in the accompanying product supplement, index supplement and prospectus.
We also urge you to consult with your investment, legal, tax, accounting and other advisers in connection with your
investment in the securities.
|
§
|
The securities provide a minimum payment at maturity of only 15%
of your principal. The terms of the securities differ from those of ordinary debt securities in that they provide a
minimum payment at maturity of only 15% of the stated principal amount at maturity. If the securities have not been automatically
redeemed prior to maturity and if the final share price of either of the underlying shares is less than 85% of its
respective initial share price, meaning that either of the underlying shares has declined by an amount greater than the buffer
amount of 15%, you will lose 1% for every 1% decline in the final share price of the worst performing underlying shares from its
initial share price beyond the buffer amount of 15%. In this case, the payment at maturity will be less than the stated principal
amount. You could lose up to 85% of your investment in the securities.
|
|
§
|
The securities do not provide for the regular payment of interest
and may pay no interest over the entire term of the securities. The terms of the securities differ from those of ordinary
debt securities in that they do not provide for the regular payment of interest. Instead, the securities will pay a contingent
monthly coupon but only if the determination closing price of each of the underlying shares is at or above 85% of its respective
initial share price, which we refer to as the coupon barrier level, on the related observation date. If, on the other hand, the
determination closing price of either of the underlying shares is lower than the respective coupon barrier level on the relevant
observation date for any interest period, we will pay no coupon on the applicable coupon payment date. However, if the contingent
monthly coupon is not paid on any coupon payment date because the determination closing price of either of the underlying shares
is less than the respective coupon barrier level on the related observation date, such unpaid contingent monthly coupon will be
paid on a later coupon payment date but only if the determination closing price of each of the underlying shares on such later
observation date is greater than or equal to the respective coupon barrier level. Therefore, you will not receive such unpaid contingent
monthly coupon if the determination closing price of either of the underlying shares is less than its respective coupon barrier
level on each subsequent observation date. It is possible that the determination closing price of one or both of the underlying
shares could remain below the respective coupon barrier level(s) for extended periods of time or even throughout the entire 5-year
term of the securities so that you will receive few or no contingent monthly coupons. If you do not earn sufficient contingent
monthly coupons over the term of the securities, the overall return on the securities may be less than the amount that would be
paid on a conventional debt security of ours of comparable maturity.
|
|
§
|
You are exposed to the price risk of each of the underlying shares,
with respect to both the contingent monthly coupons, if any, and the payment at maturity. Your
return on the securities is not linked to a basket consisting of each of the underlying shares. Rather, it will be contingent upon
the independent performance of each of the underlying shares. Unlike an instrument with a return linked to a basket of underlying
assets, in which risk is mitigated and diversified among all the components of the basket, you will be exposed to the risks related
to each of the underlying shares. Poor performance by either of the underlying
shares over the term of the securities may negatively affect your return and will not be offset or mitigated by any positive performance
by the other underlying shares. To receive any contingent monthly coupons, each
of the underlying shares must close at or above its respective coupon barrier level on the
applicable observation date. In addition, if either of the underlying shares has
declined to below 85% of its respective initial share price as of the final observation date, meaning that either
of the underlying shares has declined by an amount greater than the buffer amount of 15%, you will lose 1% for every 1% decline
in the final share price of the worst performing underlying shares from its initial share price beyond the buffer amount of 15%,
even if the other underlying shares has appreciated or has not declined as much. Under this scenario, the value of any such payment
will be less than the stated principal amount. Accordingly, your investment is subject to the price risk of each of the underlying
shares.
|
|
§
|
Investing in the securities exposes investors to risks associated with investments in securities with a concentration in
the biotechnology sector. The stocks included in the S&P Biotechnology Select IndustryTM Index and that are
generally tracked by the SPDR® S&P® Biotech ETF are stocks of companies primarily engaged in
research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering. Because the
value of the securities is linked to the performance of the underlying shares, an investment in the securities exposes investors
to risks associated with investments in securities with a concentration in the biotechnology sector. Industry-specific risks to
which companies in the biotechnology sector are subject may include the following:
|
|
o
|
After spending heavily on research and development, their products or services may not prove commercially successful or may
become obsolete quickly;
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
|
o
|
The biotechnology industry may be subject to greater governmental regulation than other industries, and changes in governmental
policies and the need for regulatory approvals may have a material adverse effect on the industry;
|
|
o
|
Companies in the biotechnology industry are subject to risks arising from new technologies and competitive pressures; and
|
|
o
|
Companies in the biotechnology industry are heavily dependent on patents and intellectual property rights. The loss or impairment
of these rights may adversely affect the profitability of these companies.
|
The XBI Shares may be subject to
increased price volatility as it is linked to a single industry, market or sector and may be more susceptible to adverse economic,
market, political or regulatory occurrences affecting that industry, market or sector. The price of the XBI Shares may be, and
has recently been, volatile, and we can give you no assurance that the volatility will lessen.
|
§
|
Investing in the securities exposes investors to risks associated with investments with a concentration in the energy sector.
The stocks included in the Energy Select Sector Index and that are generally tracked by the XLE Shares are stocks of companies
whose primary business is directly associated with the energy sector, including the following sub-sectors: (i) oil, gas and consumable
fuels and (ii) energy equipment and services. Because the value of the securities is linked to the performance of the XLE Shares,
an investment in the securities exposes investors to risks associated with investments in securities with a concentration in the
energy sector.
|
Energy companies develop and produce
crude oil and natural gas and/or provide drilling and other energy resources production and distribution related services. Stock
prices for these types of companies are mainly affected by the business, financial and operating condition of the particular company,
as well as changes in prices for oil, gas and other types of fuels, which in turn largely depend on supply and demand for various
energy products and services. Some of the factors that may influence supply and demand for energy products and services include:
general economic conditions and growth rates, weather conditions, the cost of exploring for, producing and delivering oil and gas,
technological advances affecting energy efficiency and energy consumption, the ability of the Organization of the Petroleum Exporting
Countries (OPEC) to set and maintain production levels of oil, currency fluctuations, inflation, natural disasters, civil unrest,
acts of sabotage or terrorism and other regional or global events. The profitability of energy companies may also be adversely
affected by existing and future laws, regulations, government actions and other legal requirements relating to protection of the
environment, health and safety matters and others that may increase the costs of conducting their business or may reduce or delay
available business opportunities. Increased supply or weak demand for energy products and services, as well as various developments
leading to higher costs of doing business or missed business opportunities, would adversely impact the performance of companies
in the energy sector. The value of the securities may be subject to greater volatility and be more adversely affected by a single
economic, political or regulatory occurrence affecting the energy sector or one of the sub-sectors of the energy sector than a
different investment linked to securities of a more broadly diversified group of issuers.
|
§
|
The contingent monthly coupon, if any, is based only on the determination closing prices of the underlying shares on the
related monthly observation date at the end of the related interest period.
Whether the contingent monthly coupon will be paid on any coupon payment date will be determined at the end of the relevant
interest period based on the determination closing price of each of the underlying shares on the relevant monthly observation date.
As a result, you will not know whether you will receive the contingent monthly coupon on any coupon payment date until near the
end of the relevant interest period. Moreover, because the contingent monthly coupon is based solely on the price of each of the
underlying shares on monthly observation dates, if the determination closing price of either of the underlying shares on any observation
date is below its respective coupon barrier level, you will receive no coupon for the related interest period even if the price(s)
of one or both of the underlying shares were higher on other days during that interest period.
|
|
§
|
Investors will not participate in any appreciation in the price of either of the underlying shares. Investors will not
participate in any appreciation in the price of the underlying shares from their initial share prices, and the return on the securities
will be limited to the contingent monthly coupon that is paid with respect to each observation date on which each determination
closing price is greater than or equal to its respective coupon barrier level, if any.
|
|
§
|
The market price will be influenced by many unpredictable factors.
Several factors, many of which are beyond our control, will influence the value of the securities
in the secondary market and the price at which MS & Co. may be willing to purchase or sell the securities in the secondary
market. We expect that generally the level of interest rates available in the market and the prices of the underlying
shares on any day, including in relation to the respective
coupon barrier levels, will affect the value of the securities more than any other factors. Other factors that may influence the
value of the securities include:
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
|
o
|
the trading price and volatility (frequency and magnitude of changes in value) of the underlying shares and the stocks constituting
their respective share underlying indices,
|
|
o
|
whether the determination closing price of either of the underlying shares has been below its respective coupon barrier level
on any observation date,
|
|
o
|
dividend rates on the stocks constituting the share underlying indices,
|
|
o
|
geopolitical conditions and economic, financial, political, regulatory or judicial events that affect the underlying shares
or equity markets generally and which may affect the prices of the underlying shares,
|
|
o
|
the time remaining until the securities mature,
|
|
o
|
interest and yield rates in the market,
|
|
o
|
the availability of comparable instruments,
|
|
o
|
the occurrence of certain events affecting the underlying shares that may or may not require an adjustment to the adjustment
factor,
|
|
o
|
the composition of the underlyings and changes in the constituents of the underlying shares, and
|
|
o
|
any actual or anticipated changes in our credit ratings or credit spreads.
|
Some
or all of these factors will influence the price that you will receive if you sell your securities prior to maturity. For example,
you may have to sell your securities at a substantial discount from the stated principal amount of $1,000 per security if the price
of either of the underlying shares at the time of sale is near or below its coupon barrier level or if market interest rates rise.
Generally,
the longer the time remaining to maturity, the more the market price of the securities will be affected by the other factors described
above. The price of any or both of the underlying shares may be, and have recently been, volatile, and we can give you no assurance
that the volatility will lessen. The prices of one or both of the underlying shares may decrease and be below the respective
coupon barrier level(s) on each observation date so that you will receive no return on your investment, and one or both of the
underlying shares may decline by an amount greater than the buffer amount as of the final observation date so that you lose some
or a significant portion of your initial investment in the securities. There can be no assurance that the closing price of each
of the underlying shares will be at or above their respective coupon barrier level on any observation date so that you will receive
a coupon payment on the securities for the applicable interest period, or that neither of the underlying shares will decline by
an amount greater than the buffer amount of 15% as of the final observation date so that you do not suffer a loss on your initial
investment in the securities. See “SPDR®
S&P® Biotech ETF Overview” and
“Energy Select Sector SPDR® Fund Overview”
below.
|
§
|
The securities are subject to our credit risk, and any actual or anticipated changes to our credit ratings or credit spreads
may adversely affect the market value of the securities. You are dependent on our ability to pay all amounts due on the securities
on each coupon payment date, upon automatic redemption and at maturity and therefore you are subject to our credit risk. The securities
are not guaranteed by any other entity. If we default on our obligations under the securities, your investment would be at risk
and you could lose some or all of your investment. As a result, the market value of the securities prior to maturity will be affected
by changes in the market’s view of our creditworthiness. Any actual or anticipated decline in our credit ratings or increase
in the credit spreads charged by the market for taking our credit risk is likely to adversely affect the market value of the securities.
|
|
§
|
As a finance subsidiary, MSFL has no independent operations and will have no independent assets. As a finance subsidiary,
MSFL has no independent operations beyond the issuance and administration of its securities and will have no independent assets
available for distributions to holders of MSFL securities if they make claims in respect of such securities in a bankruptcy, resolution
or similar proceeding. Accordingly, any recoveries by such holders will be limited to those available under the related guarantee
by Morgan Stanley and that guarantee will rank pari passu with all other unsecured, unsubordinated obligations of Morgan
Stanley. Holders will have recourse only to a single claim against Morgan Stanley and its assets under the guarantee. Holders of
securities issued by MSFL should accordingly assume that in any such proceedings they would not have any priority over and should
be treated pari passu with the claims of other unsecured, unsubordinated creditors of Morgan Stanley, including holders
of Morgan Stanley-issued securities.
|
|
§
|
Reinvestment risk. The term
of your investment in the securities may be shortened due to the automatic early redemption feature of the securities. If the securities
are redeemed prior to maturity, you will receive no more contingent monthly coupons and may be forced to invest in a lower interest
rate environment and may not be able to reinvest at comparable
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
terms
or returns. However, under no circumstances will the securities be redeemed in the first year-and-a-half of the term of
the securities.
|
§
|
The antidilution adjustments the calculation agent is required to make do not cover every event that could affect the underlying
shares. MS & Co., as calculation agent, will adjust the adjustment factors for certain events affecting the underlying
shares. However, the calculation agent will not make an adjustment for every event that can affect the underlying shares. If an
event occurs that does not require the calculation agent to adjust an adjustment factor, the market price of the securities
may be materially and adversely affected.
|
|
§
|
The securities will not be listed on any securities exchange and secondary trading may be limited,
and accordingly, you should be willing to hold your securities for the entire 5-year term of the securities. The securities
will not be listed on any securities exchange. Therefore, there may be little or no secondary market for the securities. MS &
Co. may, but is not obligated to, make a market in the securities and, if it once chooses to make a market, may cease doing so
at any time. When it does make a market, it will generally do so for transactions of routine secondary market size at prices based
on its estimate of the current value of the securities, taking into account its bid/offer spread, our credit spreads, market volatility,
the notional size of the proposed sale, the cost of unwinding any related hedging positions, the time remaining to maturity and
the likelihood that it will be able to resell the securities. Even if there is a secondary market, it may not provide enough liquidity
to allow you to trade or sell the securities easily. Since other broker-dealers may not participate significantly in the secondary
market for the securities, the price at which you may be able to trade your securities is likely to depend on the price, if any,
at which MS & Co. is willing to transact. If, at any time, MS & Co. were to cease making a market in the securities, it
is likely that there would be no secondary market for the securities. Accordingly, you should be willing to hold your securities
to maturity.
|
|
§
|
The rate we are willing to pay for securities of this type, maturity and issuance size is likely to be lower than the rate
implied by our secondary market credit spreads and advantageous to us. Both the lower rate and the inclusion of costs associated
with issuing, selling, structuring and hedging the securities in the original issue price reduce the economic terms of the securities,
cause the estimated value of the securities to be less than the original issue price and will adversely affect secondary market
prices. Assuming no change in market conditions or any other relevant factors, the prices, if any, at which dealers, including
MS & Co., may be willing to purchase the securities in secondary market transactions will likely be significantly lower than
the original issue price, because secondary market prices will exclude the issuing, selling, structuring and hedging-related costs
that are included in the original issue price and borne by you and because the secondary market prices will reflect our secondary
market credit spreads and the bid-offer spread that any dealer would charge in a secondary market transaction of this type as well
as other factors.
|
The inclusion of the costs of issuing,
selling, structuring and hedging the securities in the original issue price and the lower rate we are willing to pay as issuer
make the economic terms of the securities less favorable to you than they otherwise would be.
However, because the costs associated
with issuing, selling, structuring and hedging the securities are not fully deducted upon issuance, for a period of up to 6 months
following the issue date, to the extent that MS & Co. may buy or sell the securities in the secondary market, absent changes
in market conditions, including those related to the underlying shares, and to our secondary market credit spreads, it would do
so based on values higher than the estimated value, and we expect that those higher values will also be reflected in your brokerage
account statements.
|
§
|
The estimated value of the securities is determined by reference to our pricing and valuation models, which may differ from
those of other dealers, and is not a maximum or minimum secondary market price. These pricing and valuation models are proprietary
and rely in part on subjective views of certain market inputs and certain assumptions about future events, which may prove to be
incorrect. As a result, because there is no market-standard way to value these types of securities, our models may yield a higher
estimated value of the securities than those generated by others, including other dealers in the market, if they attempted to value
the securities. In addition, the estimated value on the pricing date does not represent a minimum or maximum price at which dealers,
including MS & Co., would be willing to purchase your securities in the secondary market (if any exists) at any time. The value
of your securities at any time after the date of this document will vary based on many factors that cannot be predicted with accuracy,
including our creditworthiness and changes in market conditions. See also “The market price will be influenced by many unpredictable
factors” above.
|
|
§
|
Adjustments to the underlying shares or the indices tracked by the underlying shares could adversely affect the value of
the securities. The investment advisor to each of the underlying shares (SSGA Funds Management Inc. for each of the underlying
shares) seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the
relevant share underlying index. Pursuant to its investment strategy or otherwise, the
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
investment advisor may add, delete
or substitute the stocks composing the respective underlying shares. Any of these actions could adversely affect the price of the
respective underlying shares and, consequently, the value of the securities. The publishers of the share underlying indices are
responsible for calculating and maintaining the share underlying indices. They may add, delete or substitute the securities constituting
the share underlying indices or make other methodological changes that could change the value of the share underlying indices,
and, consequently, the price of the underlying shares and the value of the securities. The publishers of the share underlying indices
may discontinue or suspend calculation or publication of a share underlying index at any time. In these circumstances, the calculation
agent will have the sole discretion to substitute a successor index that is comparable to the discontinued share underlying index
and will be permitted to consider indices that are calculated and published by the calculation agent or any of its affiliates.
|
§
|
The performance and market price of either of the
underlying shares, particularly during periods of market volatility, may not correlate with the performance of its respective
share underlying index, the performance of the component securities of such share underlying index or the net asset value per
share of such underlying shares. The underlying shares do not fully replicate their respective share underlying indices,
and each may hold securities that are different than those included in its respective share underlying index. In addition,
the performance of each of the underlying shares will reflect additional transaction costs and fees that are not included in the
calculation of the share underlying indices. All of these factors may lead to a lack of correlation between the performance
of each of the underlying shares and its respective share underlying index. In addition, corporate actions (such as mergers
and spin-offs) with respect to the equity securities underlying each of the underlying shares may impact the variance between
the performance of each of the underlying shares and its respective share underlying index. Finally, because the shares
of each of the underlying shares are traded on an exchange and are subject to market supply and investor demand, the market
price of one share of each of the underlying shares may differ from the net asset value per share of such underlying shares.
|
In particular, during periods of
market volatility, or unusual trading activity, trading in the securities underlying each of the underlying shares may be disrupted
or limited, or such securities may be unavailable in the secondary market. Under these circumstances, the liquidity of each
underlying shares may be adversely affected, market participants may be unable to calculate accurately the net asset value per
share of each of the underlying shares, and their ability to create and redeem shares of each of the underlying shares may be disrupted.
Under these circumstances, the market price of shares of each of the underlying shares may vary substantially from the net asset
value per share of each underlying share or the level of its respective share underlying index.
For all of the foregoing reasons,
the performance of each of the underlying shares may not correlate with the performance of its respective share underlying index,
the performance of the component securities of such share underlying index or the net asset value per share of such underlying
shares. Any of these events could materially and adversely affect the prices of each of the underlying shares and, therefore,
the value of the securities. Additionally, if market volatility or these events were to occur on the final observation date, the
calculation agent would maintain discretion to determine whether such market volatility or events have caused a market disruption
event to occur, and such determination would affect the payment at maturity of the securities. If the calculation agent determines
that no market disruption event has taken place, the payment at maturity would be based solely on the published closing price per
share of each of the underlying shares on the final observation date, even if either of the underlying shares is underperforming
its respective share underlying index or the component securities of such share underlying index and/or trading below the net asset
value per share of such underlying shares.
|
§
|
Not equivalent to investing in the underlying shares or the stocks
composing the share underlying indices. Investing in the securities is not equivalent to
investing in the underlying shares, the share underlying indices or the stocks that constitute the share underlying indices. Investors
in the securities will not have voting rights or rights to receive dividends or other distributions or any other rights with respect
to the underlying shares or the stocks that constitute the share underlying indices.
|
|
§
|
Hedging and trading activity by our affiliates could potentially affect the value of the securities. One or more of
our affiliates and/or third-party dealers expect to carry out hedging activities related to the securities (and to other instruments
linked to the underlying shares and the share underlying indices), including trading in the underlying shares. As a result, these
entities may be unwinding or adjusting hedge positions during the term of the securities, and the hedging strategy may involve
greater and more frequent dynamic adjustments to the hedge as the final observation date approaches. Some of our affiliates also
trade the underlying shares and other financial instruments related to the underlying shares and the share underlying indices on
a regular basis as part of their general broker-dealer and other businesses. Any of these hedging or trading activities on or prior
to the pricing date could potentially increase the initial share price of either of the underlying shares and, therefore, could
increase (i) the value at or above which such underlying shares must close on the
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
redemption determination dates so
that the securities are redeemed prior to maturity for the early redemption payment (depending also on the performance of the other
underlying shares), (ii) the coupon barrier level for such underlying shares, which is the value at or above which the underlying
shares must close on the observation dates so that you receive a contingent monthly coupon on the securities (depending also on
the performance of the other underlying shares), and (iii) the value at or above which such underlying shares must close on the
final observation date so that you are not exposed to the negative performance of the worst performing underlying shares at maturity
(depending also on the performance of the other underlying shares). Additionally, such hedging or trading activities during the
term of the securities could potentially affect the value of either of the underlying shares on the redemption determination dates
and the observation dates and, accordingly, whether we redeem the securities prior to maturity, whether we pay a contingent monthly
coupon on the securities and the amount of cash you will receive at maturity.
|
§
|
The calculation agent, which is a subsidiary of Morgan Stanley and an affiliate of MSFL, will make determinations with respect
to the securities. As calculation agent, MS & Co. will determine the initial share prices, the coupon barrier levels, the
final share prices, the payment at maturity, whether you receive a contingent monthly coupon on each coupon payment date and/or
at maturity, whether you will receive any previously unpaid contingent monthly coupons, whether the securities will be redeemed
on any early redemption date, whether a market disruption event has occurred and whether to make any adjustments to the adjustment
factors. Moreover, certain determinations made by MS & Co., in its capacity as calculation agent, may require it to exercise
discretion and make subjective judgments, such as with respect to the occurrence or non-occurrence of market disruption events
or calculation of the determination closing price in the event of a market disruption event. These potentially subjective determinations
may affect the payout to you upon an automatic early redemption or at maturity. For further information regarding these types of
determinations, see “Description of Auto-Callable Securities—Auto-Callable Securities Linked to Underlying Shares”
and “—Calculation Agent and Calculations” in the accompanying product supplement. In addition, MS & Co. has
determined the estimated value of the securities on the pricing date.
|
|
§
|
The U.S. federal income tax consequences of an investment in the securities are uncertain. There is no direct legal
authority as to the proper treatment of the securities for U.S. federal income tax purposes, and, therefore, significant aspects
of the tax treatment of the securities are uncertain.
|
Please read the discussion under
“Additional Information—Tax considerations” in this document concerning the U.S. federal income tax consequences
of an investment in the securities. We intend to treat a security for U.S. federal income tax purposes as a single financial contract
that provides for a coupon that will be treated as gross income to you at the time received or accrued, in accordance with your
regular method of tax accounting. Under this treatment, the ordinary income treatment of the coupon payments, in conjunction with
the capital loss treatment of any loss recognized upon the sale, exchange or settlement of the securities, could result in adverse
tax consequences to holders of the securities because the deductibility of capital losses is subject to limitations. We do not
plan to request a ruling from the Internal Revenue Service (the “IRS”) regarding the tax treatment of the securities,
and the IRS or a court may not agree with the tax treatment described herein. If the IRS were successful in asserting an alternative
treatment for the securities, the timing and character of income or loss on the securities might differ significantly from the
tax treatment described herein. For example, under one possible treatment, the IRS could seek to recharacterize the securities
as debt instruments. In that event, U.S. Holders (as defined below) would be required to accrue into income original issue discount
on the securities every year at a “comparable yield” determined at the time of issuance (as adjusted based on the difference,
if any, between the actual and the projected amount of any contingent payments on the securities) and recognize all income and
gain in respect of the securities as ordinary income. The risk that financial instruments providing for buffers, triggers or similar
downside protection features, such as the securities, would be recharacterized as debt is greater than the risk of recharacterization
for comparable financial instruments that do not have such features.
Non-U.S. Holders (as defined
below) should note that we currently intend to withhold on any coupon paid to Non-U.S. Holders generally at a rate of 30%, or at
a reduced rate specified by an applicable income tax treaty under an “other income” or similar provision, and will
not be required to pay any additional amounts with respect to amounts withheld.
In 2007, the U.S. Treasury Department
and the IRS released a notice requesting comments on the U.S. federal income tax treatment of “prepaid forward contracts”
and similar instruments. While it is not clear whether the securities would be viewed as similar to the prepaid forward contracts
described in the notice, it is possible that any Treasury regulations or other guidance promulgated after consideration of these
issues could materially and adversely affect the tax consequences of an investment in the securities, possibly with retroactive
effect. The notice focuses on a number of issues, the most relevant of which for holders of the securities are the character and
timing of income or loss and the degree, if any, to which income realized by non-U.S. investors should be subject to withholding
tax. Both U.S. and Non-U.S. Holders should
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
consult their tax advisers regarding
the U.S. federal income tax consequences of an investment in the securities, including possible alternative treatments, the issues
presented by this notice and any tax consequences arising under the laws of any state, local or non-U.S. taxing jurisdiction.
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
SPDR® S&P®
Biotech ETF Overview
The SPDR® S&P® Biotech
ETF is an exchange-traded fund managed by SSGA Funds Management, Inc., which seeks to provide investment results that correspond
generally to the price and yield performance, before fees and expenses, of the S&P Biotechnology Select IndustryTM Index.
SPDR® Series Trust (the “Trust”) is a registered investment company that consists of numerous separate
investment portfolios, including the SPDR® S&P® Biotech ETF. Information provided to
or filed with the Securities and Exchange Commission (the “Commission”) by the Trust pursuant to the Securities Act
of 1933 and the Investment Company Act of 1940 can be located by reference to Commission file numbers 333-57793 and 811-08839,
respectively, through the Commission’s website at www.sec.gov. In addition, information may be obtained from other publicly
available sources. Neither the issuer nor the agent makes any representation that any such publicly available information regarding
the SPDR® S&P® Biotech ETF is accurate or complete.
Information as of market close on September
30, 2019:
Ticker Symbol:
|
XBI UP
|
Current Stock Price:
|
$76.25
|
52 Weeks Ago:
|
$94.59
|
52 Week High (on 10/3/2018):
|
$94.90
|
52 Week Low (on 12/24/2018):
|
$65.42
|
The following graph sets forth the daily closing
values of the XBI Shares for the period from January 1, 2014 through September 30, 2019. The related table sets forth the published
high and low closing prices, as well as the end-of-quarter closing prices, of the XBI Shares for each quarter in the same period.
The closing price of the XBI Shares on September 30, 2019 was $76.25. We obtained the information in the table and graph below
from Bloomberg Financial Markets, without independent verification. The historical performance of the XBI Shares should not be
taken as an indication of its future performance, and no assurance can be given as to the price of the XBI Shares at any time,
including on the redemption determination dates or the observation dates.
Shares of the SPDR® S&P® Biotech ETF – Daily Closing Prices
January 1, 2014 to September 30, 2019
|
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
SPDR® S&P® Biotech ETF (CUSIP: 78464A870)
|
High ($)
|
Low ($)
|
Period End ($)
|
2014
|
|
|
|
First Quarter
|
56.90
|
42.97
|
47.49
|
Second Quarter
|
51.35
|
40.27
|
51.35
|
Third Quarter
|
54.30
|
44.87
|
51.99
|
Fourth Quarter
|
63.45
|
48.48
|
62.21
|
2015
|
|
|
|
First Quarter
|
79.33
|
61.43
|
75.17
|
Second Quarter
|
86.57
|
68.78
|
84.08
|
Third Quarter
|
90.36
|
60.02
|
62.25
|
Fourth Quarter
|
72.62
|
61.16
|
70.08
|
2016
|
|
|
|
First Quarter
|
67.83
|
45.73
|
51.66
|
Second Quarter
|
59.87
|
49.55
|
54.09
|
Third Quarter
|
68.83
|
55.11
|
66.29
|
Fourth Quarter
|
68.13
|
53.31
|
59.19
|
2017
|
|
|
|
First Quarter
|
72.32
|
59.59
|
69.34
|
Second Quarter
|
80.31
|
66.84
|
77.18
|
Third Quarter
|
86.57
|
74.47
|
86.57
|
Fourth Quarter
|
88.51
|
79.95
|
84.87
|
2018
|
|
|
|
First Quarter
|
97.03
|
85.31
|
87.73
|
Second Quarter
|
101.15
|
82.90
|
95.19
|
Third Quarter
|
100.84
|
93.08
|
95.87
|
Fourth Quarter
|
94.90
|
65.42
|
71.75
|
2019
|
|
|
|
First Quarter
|
91.92
|
71.21
|
90.54
|
Second Quarter
|
93.80
|
79.44
|
87.71
|
Third Quarter (through September 30, 2019)
|
88.89
|
76.25
|
76.25
|
This document relates only to the securities offered hereby
and does not relate to the XBI Shares. We have derived all disclosures contained in this document regarding the Trust
from the publicly available documents described above. In connection with the offering of the securities, neither we
nor the agent has participated in the preparation of such documents or made any due diligence inquiry with respect to the Trust. Neither
we nor the agent makes any representation that such publicly available documents or any other publicly available information regarding
the Trust is accurate or complete. Furthermore, we cannot give any assurance that all events occurring prior to the
date hereof (including events that would affect the accuracy or completeness of the publicly available documents described above)
that would affect the trading price of the XBI Shares (and therefore the price of the XBI Shares at the time we price the securities)
have been publicly disclosed. Subsequent disclosure of any such events or the disclosure of or failure to disclose material
future events concerning the Trust could affect the value received with respect to the securities and therefore the value of the
securities.
Neither we nor any of our affiliates makes any representation
to you as to the performance of the XBI Shares.
We and/or our affiliates may presently or from time to time engage
in business with the Trust. In the course of such business, we and/or our affiliates may acquire non-public information
with respect to the Trust, and neither we nor any of our affiliates undertakes to disclose any such information to you. In
addition, one or more of our affiliates may publish research reports with respect to the XBI Shares. The statements
in the preceding two sentences are not intended to affect the rights of investors in the securities under the securities laws. As
a prospective purchaser of the securities, you should undertake an independent investigation of the Trust as in your judgment is
appropriate to make an informed decision with respect to an investment linked to the XBI Shares.
“S&P®”, “SPDR®”
and “S&P Biotechnology Select IndustryTM Index” are trademarks of Standard & Poor’s Financial
Services LLC (“S&P”), an affiliate of The McGraw-Hill Companies, Inc. (“MGH”). The securities are not
sponsored, endorsed, sold, or promoted by S&P, MGH or the Trust. S&P, MGH and the Trust make no representations or warranties
to the owners of the securities or any member of the public regarding the advisability of investing in the Securities. S&P,
MGH and the Trust have no obligation or liability in connection with the operation, marketing, trading or sale of the securities.
The S&P
Biotechnology Select IndustryTM Index. The S&P Biotechnology Select IndustryTM Index
(Bloomberg ticker SPSIBI) is managed by S&P Dow Jones Indices LLC and is a modified equally weighted index that is designed
to measure the performance of stocks in the S&P® Total Market Index that are classified under the Global Industry
Classification Standard (“GICS®”) biotechnology sub-industry.
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
Energy Select Sector SPDR®
Fund Overview
The Energy Select Sector SPDR® Fund is an exchange-traded
fund managed by the Select Sector SPDR® Trust (the “Trust”), a registered investment company. The Trust
consists of nine separate investment portfolios, including the Energy Select Sector SPDR® Fund. The Energy Select
Sector SPDR® Fund seeks investment results that correspond generally to the price and yield performance, before
fees and expenses, of the Energy Select Sector Index. It is possible that this fund may not fully replicate the performance of
the Energy Select Sector Index due to the temporary unavailability of certain securities in the secondary market or due to other
extraordinary circumstances. Information provided to or filed with the Securities and Exchange Commission (the “Commission”)
by the Trust pursuant to the Securities Act of 1933 and the Investment Company Act of 1940 can be located by reference to Commission
file numbers 333-57791 and 811-08837, respectively, through the Commission’s website at www.sec.gov. In addition, information
may be obtained from other publicly available sources. Neither the issuer nor the agent makes any representation that any such
publicly available information regarding the issuer of the XLE Shares is accurate or complete.
Information as of market close on September 30, 2019:
Ticker Symbol:
|
XLE UP
|
Current Share Price:
|
$59.20
|
52 Weeks Ago:
|
$76.79
|
52 Week High (on 10/9/2018):
|
$77.79
|
52 Week Low (on 12/24/2018):
|
$53.84
|
Shares of the
Energy Select Sector SPDR® Fund — Daily Closing Prices
January 1,
2014 to September 30, 2019
|
|
The following graph sets forth the daily closing values of the
XLE Shares for the period from January 1, 2014 through September 30, 2019. The related table sets forth the published high and
low closing prices, as well as the end-of-quarter closing prices, of the XLE Shares for each quarter in the same period. The closing
price of the XLE Shares on September 30, 2019 was $59.20. We obtained the information in the table and graph below from Bloomberg
Financial Markets, without independent verification. The historical performance of the XLE Shares should not be taken as an indication
of its future performance, and no assurance can be given as to the price of the XLE Shares at any time, including on the redemption
determination dates or the observation dates.
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
Energy Select Sector SPDR® Fund (CUSIP 81369Y506)
|
High ($)
|
Low ($)
|
Period End ($)
|
2014
|
|
|
|
First Quarter
|
89.06
|
81.89
|
89.06
|
Second Quarter
|
101.29
|
88.45
|
100.10
|
Third Quarter
|
100.58
|
90.62
|
90.62
|
Fourth Quarter
|
88.77
|
73.36
|
79.16
|
2015
|
|
|
|
First Quarter
|
82.29
|
72.86
|
77.58
|
Second Quarter
|
82.94
|
74.64
|
75.16
|
Third Quarter
|
74.54
|
59.22
|
61.20
|
Fourth Quarter
|
71.40
|
58.78
|
60.55
|
2016
|
|
|
|
First Quarter
|
63.75
|
51.80
|
61.92
|
Second Quarter
|
69.50
|
60.18
|
68.24
|
Third Quarter
|
71.80
|
65.27
|
70.61
|
Fourth Quarter
|
77.83
|
67.77
|
75.32
|
2017
|
|
|
|
First Quarter
|
76.17
|
68.24
|
69.90
|
Second Quarter
|
70.90
|
63.95
|
64.92
|
Third Quarter
|
68.49
|
62.00
|
68.48
|
Fourth Quarter
|
72.60
|
67.08
|
72.26
|
2018
|
|
|
|
First Quarter
|
78.03
|
66.02
|
67.41
|
Second Quarter
|
78.91
|
66.06
|
75.94
|
Third Quarter
|
77.37
|
71.91
|
75.74
|
Fourth Quarter
|
77.79
|
53.84
|
57.35
|
2019
|
|
|
|
First Quarter
|
67.29
|
57.90
|
66.12
|
Second Quarter
|
68.61
|
58.77
|
63.71
|
Third Quarter (through September 30, 2019)
|
64.44
|
55.85
|
59.20
|
This document relates only to the securities offered hereby
and does not relate to the XLE Shares. We have derived all disclosures contained in this document regarding the Trust from the
publicly available documents described above. In connection with the offering of the securities, neither we nor the agent has participated
in the preparation of such documents or made any due diligence inquiry with respect to the Trust. Neither we nor the agent makes
any representation that such publicly available documents or any other publicly available information regarding the Trust is accurate
or complete. Furthermore, we cannot give any assurance that all events occurring prior to the date hereof (including events that
would affect the accuracy or completeness of the publicly available documents described above) that would affect the trading price
of the XLE Shares (and therefore the price of the XLE Shares at the time we price the securities) have been publicly disclosed.
Subsequent disclosure of any such events or the disclosure of or failure to disclose material future events concerning the Trust
could affect the value received with respect to the securities and therefore the value of the securities. Neither we nor any of
our affiliates makes any representation to you as to the performance of the XLE Shares.
We and/or our affiliates may presently or from time to time engage
in business with the Trust. In the course of such business, we and/or our affiliates may acquire non-public information with respect
to the Trust, and neither we nor any of our affiliates undertakes to disclose any such information to you. In addition, one or
more of our affiliates may publish research reports with respect to the XLE Shares. The statements in the preceding two sentences
are not intended to affect the rights of investors in the securities under the securities laws. As a prospective purchaser of the
securities, you should undertake an independent investigation of the Trust as in your judgment is appropriate to make an informed
decision with respect to an investment in the XLE Shares.
“Standard & Poor’s®”,
“S&P®”, “S&P 500®”, “SPDR®”, “Select Sector
SPDR” and “Select Sector SPDRs” are trademarks of Standard & Poor’s Financial Services LLC, an affiliate
of The McGraw-Hill Companies, Inc. (“MGH”). The securities are not sponsored, endorsed, sold, or promoted by S&P,
MGH or the Trust. S&P, MGH and the Trust make no representations or warranties to the owners of the securities or any member
of the public regarding the advisability of investing in the Securities. S&P, MGH and the Trust have no obligation or liability
in connection with the operation, marketing, trading or sale of the securities.
The Energy Select Sector Index.
The Energy Select Sector Index is calculated and disseminated by S&P and is designed to provide an effective representation
of the energy sector of the S&P 500® Index. The Energy Select Sector Index includes companies in the following
industries: (i) oil, gas and consumable fuels and (ii) energy equipment and services. See “Energy Select Sector Index”
in the accompanying index supplement.
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
Additional Terms of the Securities
Please read this information in conjunction with the summary
terms on the front cover of this document.
Additional Terms:
|
If the terms described herein are inconsistent with those described in the accompanying product supplement, index supplement or prospectus, the terms described herein shall control.
|
Interest
period:
|
The monthly period from and including the original issue date (in the case of the first interest period) or the previous scheduled coupon payment date, as applicable, to but excluding the following scheduled coupon payment date, with no adjustment for any postponement thereof.
|
Record
date:
|
The record date for each coupon payment date shall be the date one business day prior to such scheduled coupon payment date; provided, however, that any coupon payable at maturity (or upon early redemption) shall be payable to the person to whom the payment at maturity or early redemption payment, as the case may be, shall be payable.
|
Share
underlying indices:
|
With respect to the XBI Shares, the S&P Biotechnology
Select IndustryTM Index
With respect to the XLE
Shares, the Energy Select Sector Index
|
Share
underlying index publishers:
|
With respect to the XBI Shares, S&P Dow Jones Indices LLC,
or any successor thereof.
With respect to the XLE Shares, S&P Dow Jones Indices
LLC, or any successor thereof.
|
Day
count convention:
|
Interest will be computed on the basis of a 360-day year of twelve 30-day months.
|
Postponement
of coupon payment dates (including the maturity date) and early redemption dates:
|
If any observation date or redemption determination date is postponed due to a non-trading day or certain market disruption events with respect to either of the underlying shares so that it falls less than two business days prior to the relevant scheduled coupon payment date (including the maturity date) or early redemption date, as applicable, the coupon payment date (or the maturity date) or the early redemption date will be postponed to the second business day following that observation date or redemption determination date as postponed, and no adjustment will be made to any coupon payment, early redemption payment or payment at maturity made on that postponed date.
|
Trustee:
|
The Bank of New York Mellon
|
Calculation
agent:
|
MS & Co.
|
Issuer
notices to registered security holders, the trustee and the depositary:
|
In the event that the maturity date is postponed due to postponement
of the final observation date, the issuer shall give notice of such postponement and, once it has been determined, of the date
to which the maturity date has been rescheduled (i) to each registered holder of the securities by mailing notice of such postponement
by first class mail, postage prepaid, to such registered holder’s last address as it shall appear upon the registry books,
(ii) to the trustee by facsimile, confirmed by mailing such notice to the trustee by first class mail, postage prepaid, at its
New York office and (iii) to The Depository Trust Company (the “depositary”) by telephone or facsimile confirmed by
mailing such notice to the depositary by first class mail, postage prepaid. Any notice that is mailed to a registered holder of
the securities in the manner herein provided shall be conclusively presumed to have been duly given to such registered holder,
whether or not such registered holder receives the notice. The issuer shall give such notice as promptly as possible, and in no
case later than (i) with respect to notice of postponement of the maturity date, the business day immediately preceding the scheduled
maturity date and (ii) with respect to notice of the date to which the maturity date has been rescheduled, the business day immediately
following the final observation date as postponed.
In the event that the securities are subject to early redemption,
the issuer shall, (i) on the business day following the applicable redemption determination date, give notice of the early redemption
and the early redemption payment, including specifying the payment date of the amount due upon the early redemption, (x) to each
registered holder of the securities by mailing notice of such early redemption by first class mail, postage prepaid, to such registered
holder’s last address as it shall appear upon the registry books, (y) to the trustee by facsimile confirmed by mailing such
notice to the trustee by first class mail, postage prepaid, at its New York office and (z) to the depositary by telephone or facsimile
confirmed by mailing such notice to the depositary by first class mail, postage prepaid, and (ii) on or prior to the early redemption
date, deliver the aggregate cash amount due with respect to the securities to the trustee for delivery to the depositary, as holder
of the securities. Any notice that is mailed to a registered holder of the securities in the manner herein provided shall be conclusively
presumed to have been duly given to such registered holder, whether or not such registered holder receives the notice. This notice
shall be given by the issuer or, at the issuer’s request, by the trustee in the name and at the expense of the issuer, with
any such request to be accompanied by a copy of the notice to be given.
The issuer shall, or shall cause the calculation agent to, (i)
provide written notice to the trustee, on which notice the trustee may conclusively rely, and to the depositary of the amount of
cash to be delivered as monthly coupon with respect to each security on or prior to 10:30 a.m. (New York City time) on the business
day preceding each coupon payment date, and (ii) deliver the aggregate cash amount due with respect to the monthly coupon to the
trustee for delivery to the depositary, as holder of the securities, on the applicable coupon payment date.
The issuer shall, or shall cause the calculation agent
to, (i) provide written notice to the trustee, on which notice the trustee may conclusively rely, and to the depositary of the
amount of cash to be delivered with respect to each stated principal amount of the securities, on or prior to 10:30
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
|
a.m. (New York City time) on the business day preceding the maturity date, and (ii) deliver the aggregate cash amount due with respect to the securities to the trustee for delivery to the depositary, as holder of the securities, on the maturity date.
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
Additional Information
About the Securities
Additional Information:
|
Minimum
ticketing size:
|
$1,000 / 1 security
|
Tax considerations:
|
Prospective investors should note that the discussion under
the section called “United States Federal Taxation” in the accompanying product supplement does not apply to the securities
issued under this document and is superseded by the following discussion.
The following is a general discussion of the material U.S. federal
income tax consequences and certain estate tax consequences of the ownership and disposition of the securities. This discussion
applies only to investors in the securities who:
· purchase
the securities in the original offering; and
· hold the securities as capital assets within the meaning of Section 1221 of the Internal Revenue Code of 1986, as amended (the
“Code”).
This discussion does not describe all of the
tax consequences that may be relevant to a holder in light of the holder’s particular circumstances or to holders subject
to special rules, such as:
· certain financial institutions;
· insurance companies;
· certain
dealers and traders in securities or commodities;
· investors holding the securities as part of a “straddle,” wash sale, conversion transaction, integrated transaction
or constructive sale transaction;
· U.S. Holders (as defined below) whose functional currency is not the U.S. dollar;
· partnerships or other entities classified as partnerships for U.S. federal income tax purposes;
· regulated
investment companies;
· real
estate investment trusts; or
· tax-exempt entities, including “individual retirement accounts” or “Roth IRAs” as defined in Section 408
or 408A of the Code, respectively.
If an entity that is classified as a partnership
for U.S. federal income tax purposes holds the securities, the U.S. federal income tax treatment of a partner will generally depend
on the status of the partner and the activities of the partnership. If you are a partnership holding the securities or a partner
in such a partnership, you should consult your tax adviser as to the particular U.S. federal tax consequences of holding and disposing
of the securities to you.
As the law applicable to the U.S. federal income
taxation of instruments such as the securities is technical and complex, the discussion below necessarily represents only a general
summary. The effect of any applicable state, local or non-U.S. tax laws is not discussed, nor are any alternative minimum tax consequences
or consequences resulting from the Medicare tax on investment income. Moreover, the discussion below does not address the consequences
to taxpayers subject to special tax accounting rules under Section 451(b) of the Code.
This discussion is based on the Code, administrative
pronouncements, judicial decisions and final, temporary and proposed Treasury regulations, all as of the date hereof, changes to
any of which subsequent to the date hereof may affect the tax consequences described herein. Persons considering the purchase of
the securities should consult their tax advisers with regard to the application of the U.S. federal income tax laws to their particular
situations as well as any tax consequences arising under the laws of any state, local or non-U.S. taxing jurisdiction.
General
Due to the absence of statutory, judicial or
administrative authorities that directly address the treatment of the securities or instruments that are similar to the securities
for U.S. federal income tax purposes, no assurance can be given that the IRS or a court will agree with the tax treatment described
herein. We intend to treat a security for U.S. federal income tax purposes as a single financial contract that provides for a coupon
that will be treated as gross income to you at the time received or accrued in accordance with your regular method of tax accounting.
In the opinion of our counsel, Davis Polk & Wardwell LLP, this treatment of the securities is reasonable under current law;
however, our counsel has advised us that it is unable to conclude affirmatively that this treatment is more likely than not to
be upheld, and that alternative treatments are possible. Moreover, our counsel’s opinion is based on market conditions as
of the date of this preliminary pricing supplement and is subject to confirmation on the pricing date.
You should consult your tax adviser
regarding all aspects of the U.S. federal tax
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
|
consequences of an investment in the securities
(including possible alternative treatments of the securities). Unless otherwise stated, the following discussion is based on the
treatment of each security as described in the previous paragraph.
Tax Consequences to U.S. Holders
This section applies to you only if you are
a U.S. Holder. As used herein, the term “U.S. Holder” means a beneficial owner of a security that is, for U.S. federal
income tax purposes:
· a
citizen or individual resident of the United States;
· a
corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state
thereof or the District of Columbia; or
· an estate or trust the income of which is subject to U.S. federal income taxation regardless of its source.
Tax Treatment of the Securities
Assuming the treatment of the securities as
set forth above is respected, the following U.S. federal income tax consequences should result.
Tax Basis. A U.S. Holder’s tax
basis in the securities should equal the amount paid by the U.S. Holder to acquire the securities.
Tax Treatment of Coupon Payments.
Any coupon payment on the securities should be taxable as ordinary income to a U.S. Holder at the time received or accrued, in
accordance with the U.S. Holder’s regular method of accounting for U.S. federal income tax purposes.
Sale, Exchange or Settlement of the
Securities. Upon a sale, exchange or settlement of the securities, a U.S. Holder should recognize gain or loss equal to the
difference between the amount realized on the sale, exchange or settlement and the U.S. Holder’s tax basis in the securities
sold, exchanged or settled. For this purpose, the amount realized does not include any coupon paid at settlement and may not include
sale proceeds attributable to an accrued coupon, which may be treated as a coupon payment. Any such gain or loss recognized should
be long-term capital gain or loss if the U.S. Holder has held the securities for more than one year at the time of the sale, exchange
or settlement, and should be short-term capital gain or loss otherwise. The ordinary income treatment of the coupon payments, in
conjunction with the capital loss treatment of any loss recognized upon the sale, exchange or settlement of the securities, could
result in adverse tax consequences to holders of the securities because the deductibility of capital losses is subject to limitations.
Possible Alternative Tax Treatments of
an Investment in the Securities
Due to the absence of authorities that directly
address the proper tax treatment of the securities, no assurance can be given that the IRS will accept, or that a court will uphold,
the treatment described above. In particular, the IRS could seek to analyze the U.S. federal income tax consequences of owning
the securities under Treasury regulations governing contingent payment debt instruments (the “Contingent Debt Regulations”).
If the IRS were successful in asserting that the Contingent Debt Regulations applied to the securities, the timing and character
of income thereon would be significantly affected. Among other things, a U.S. Holder would be required to accrue into income original
issue discount on the securities every year at a “comparable yield” determined at the time of their issuance, adjusted
upward or downward to reflect the difference, if any, between the actual and the projected amount of any contingent payments on
the securities. Furthermore, any gain realized by a U.S. Holder at maturity or upon a sale, exchange or other disposition of the
securities would be treated as ordinary income, and any loss realized would be treated as ordinary loss to the extent of the U.S.
Holder’s prior accruals of original issue discount and as capital loss thereafter. The risk that financial instruments providing
for buffers, triggers or similar downside protection features, such as the securities, would be recharacterized as debt is greater
than the risk of recharacterization for comparable financial instruments that do not have such features.
Other alternative federal income tax treatments of the
securities are possible, which, if applied, could significantly affect the timing and character of the income or loss with respect
to the securities. In 2007, the U.S. Treasury Department and the IRS released a notice requesting comments on the U.S. federal
income tax treatment of “prepaid forward contracts” and similar instruments. The notice focuses on whether to require
holders of “prepaid forward contracts” and similar instruments to accrue income over the term of their investment.
It also asks for comments on a number of related topics, including the character of income or loss with respect to these instruments;
whether short-term instruments should be subject to any such accrual regime; the relevance of factors such as the exchange–traded
status of the instruments and the
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
|
nature of the underlying property to which
the instruments are linked; whether these instruments are or should be subject to the “constructive ownership” rule,
which very generally can operate to recharacterize certain long-term capital gain as ordinary income and impose an interest charge;
and appropriate transition rules and effective dates. While it is not clear whether instruments such as the securities would be
viewed as similar to the prepaid forward contracts described in the notice, any Treasury regulations or other guidance promulgated
after consideration of these issues could materially and adversely affect the tax consequences of an investment in the securities,
possibly with retroactive effect. U.S. Holders should consult their tax advisers regarding the U.S. federal income tax consequences
of an investment in the securities, including possible alternative treatments and the issues presented by this notice.
Backup Withholding and Information Reporting
Backup withholding may apply in respect of
payments on the securities and the payment of proceeds from a sale, exchange or other disposition of the securities, unless a U.S.
Holder provides proof of an applicable exemption or a correct taxpayer identification number and otherwise complies with applicable
requirements of the backup withholding rules. The amounts withheld under the backup withholding rules are not an additional tax
and may be refunded, or credited against the U.S. Holder’s U.S. federal income tax liability, provided that the required
information is timely furnished to the IRS. In addition, information returns will be filed with the IRS in connection with
payments on the securities and the payment of proceeds from a sale, exchange or other disposition of the securities, unless the
U.S. Holder provides proof of an applicable exemption from the information reporting rules.
Tax Consequences to Non-U.S. Holders
This section applies to you only if you are
a Non-U.S. Holder. As used herein, the term “Non-U.S. Holder” means a beneficial owner of a security that is for U.S.
federal income tax purposes:
· an
individual who is classified as a nonresident alien;
· a
foreign corporation; or
· a foreign estate or trust.
The term “Non-U.S. Holder” does
not include any of the following holders:
· a
holder who is an individual present in the United States for 183 days or more in the taxable year of disposition and who is not
otherwise a resident of the United States for U.S. federal income tax purposes;
· certain
former citizens or residents of the United States; or
· a holder for whom income or gain in respect of the securities is effectively connected with the conduct of a trade or business
in the United States.
Such holders should consult their tax advisers
regarding the U.S. federal income tax consequences of an investment in the securities.
Although significant aspects of the tax treatment
of each security are uncertain, we intend to withhold on any coupon paid to a Non-U.S. Holder generally at a rate of 30% or at
a reduced rate specified by an applicable income tax treaty under an “other income” or similar provision. We will not
be required to pay any additional amounts with respect to amounts withheld. In order to claim an exemption from, or a reduction
in, the 30% withholding tax, a Non-U.S. Holder of the securities must comply with certification requirements to establish that
it is not a U.S. person and is eligible for such an exemption or reduction under an applicable tax treaty. If you are a Non-U.S.
Holder, you should consult your tax adviser regarding the tax treatment of the securities, including the possibility of obtaining
a refund of any withholding tax and the certification requirement described above.
Section 871(m) Withholding Tax on Dividend
Equivalents
Section 871(m) of the Code and Treasury regulations
promulgated thereunder (“Section 871(m)”) generally impose a 30% (or a lower applicable treaty rate) withholding tax
on dividend equivalents paid or deemed paid to Non-U.S. Holders with respect to certain financial instruments linked to U.S. equities
or indices that include U.S. equities (each, an “Underlying Security”). Subject to certain exceptions, Section 871(m)
generally applies to securities that substantially replicate the economic performance of one or more Underlying Securities, as
determined based on tests set forth in the applicable Treasury regulations (a “Specified Security”). However, pursuant
to an IRS notice, Section 871(m) will not apply to securities issued before January 1, 2021 that do not have a delta of one with
respect to any Underlying Security. Based on the terms of the securities and current market conditions, we expect that the securities
will not have a delta of one with respect to any Underlying Security on the pricing date.
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
|
However, we will provide an updated determination
in the pricing supplement. Assuming that the securities do not have a delta of one with respect to any Underlying Security, our
counsel is of the opinion that the securities should not be Specified Securities and, therefore, should not be subject to Section
871(m).
Our determination is not binding on the IRS,
and the IRS may disagree with this determination. Section 871(m) is complex and its application may depend on your particular circumstances,
including whether you enter into other transactions with respect to an Underlying Security. If Section 871(m) withholding is required,
we will not be required to pay any additional amounts with respect to the amounts so withheld. You should consult your tax adviser
regarding the potential application of Section 871(m) to the securities.
U.S. Federal Estate Tax
Individual Non-U.S. Holders and entities the
property of which is potentially includible in such an individual’s gross estate for U.S. federal estate tax purposes (for
example, a trust funded by such an individual and with respect to which the individual has retained certain interests or powers)
should note that, absent an applicable treaty exemption, the securities may be treated as U.S.-situs property subject to U.S. federal
estate tax. Prospective investors that are non-U.S. individuals, or are entities of the type described above, should consult their
tax advisers regarding the U.S. federal estate tax consequences of an investment in the securities.
Backup Withholding and Information Reporting
Information returns will be filed with the
IRS in connection with any coupon payment and may be filed with the IRS in connection with the payment at maturity on the securities
and the payment of proceeds from a sale, exchange or other disposition. A Non-U.S. Holder may be subject to backup withholding
in respect of amounts paid to the Non-U.S. Holder, unless such Non-U.S. Holder complies with certification procedures to establish
that it is not a U.S. person for U.S. federal income tax purposes or otherwise establishes an exemption. The amount of any backup
withholding from a payment to a Non-U.S. Holder will be allowed as a credit against the Non-U.S. Holder’s U.S. federal income
tax liability and may entitle the Non-U.S. Holder to a refund, provided that the required information is timely furnished to the
IRS.
FATCA
Legislation commonly referred to as “FATCA”
generally imposes a withholding tax of 30% on payments to certain non-U.S. entities (including financial intermediaries) with respect
to certain financial instruments, unless various U.S. information reporting and due diligence requirements have been satisfied.
An intergovernmental agreement between the United States and the non-U.S. entity’s jurisdiction may modify these requirements.
FATCA generally applies to certain financial instruments that are treated as paying U.S.-source interest or other U.S.-source “fixed
or determinable annual or periodical” income (“FDAP income”). Withholding (if applicable) applies to payments
of U.S.-source FDAP income and to payments of gross proceeds of the disposition (including upon retirement) of certain financial
instruments treated as providing for U.S.-source interest or dividends. Under recently proposed regulations (the preamble to which
specifies that taxpayers are permitted to rely on them pending finalization), no withholding will apply on payments of gross proceeds
(other than amounts treated as FDAP income). While the treatment of the securities is unclear, you should assume that any coupon
payment with respect to the securities will be subject to the FATCA rules. If withholding applies to the securities, we will not
be required to pay any additional amounts with respect to amounts withheld. Both U.S. and Non-U.S. Holders should consult their
tax advisers regarding the potential application of FATCA to the securities.
The discussion in the preceding paragraphs, insofar
as it purports to describe provisions of U.S. federal income tax laws or legal conclusions with respect thereto, constitutes the
full opinion of Davis Polk & Wardwell LLP regarding the material U.S. federal tax consequences of an investment in the securities.
|
Use
of proceeds and hedging:
|
The proceeds from the sale of the securities will be used by
us for general corporate purposes. We will receive, in aggregate, $1,000 per security issued, because, when we enter into hedging
transactions in order to meet our obligations under the securities, our hedging counterparty will reimburse the cost of the agent’s
commissions. The costs of the securities borne by you and described beginning on page 4 above comprise the agent’s commissions
and the cost of issuing, structuring and hedging the securities.
On or prior to the pricing date, we will hedge our anticipated
exposure in connection with the securities by entering into hedging transactions with our affiliates and/or third-party dealers.
We expect our hedging counterparties to take positions in the underlying shares, in futures and/or options contracts on the underlying
shares or any component stocks of the share underlying indices, or positions in any other available securities or instruments
that they may wish to use in
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
|
connection with such hedging. Such purchase activity could potentially increase the initial share price of one or both of the underlying shares and, therefore, could increase (i) the value at or above which such underlying shares must close on the redemption determination dates so that the securities are redeemed prior to maturity for the early redemption payment (depending also on the performance of the other underlying shares) and (ii) the coupon barrier level for such underlying shares, which is the value at or above which the underlying shares must close on the observation dates so that you receive a contingent monthly coupon on the securities (depending also on the performance of the other underlying shares) and (iii) the value at or above which such underlying shares must close on the final observation date so that you are not exposed to the negative performance of the worst performing underlying shares at maturity (depending also on the performance of the other underlying shares). These entities may be unwinding or adjusting hedge positions during the term of the securities, and the hedging strategy may involve greater and more frequent dynamic adjustments to the hedge as the final observation date approaches. Additionally, our hedging activities, as well as our other trading activities, during the term of the securities could potentially affect the value of any of the underlying shares on the redemption determination dates and other observation dates and, accordingly, whether we redeem the securities prior to maturity, whether we pay a contingent monthly coupon on the securities and the amount of cash you will receive at maturity. For further information on our use of proceeds and hedging, see “Use of Proceeds and Hedging” in the accompanying product supplement.
|
Benefit plan investor considerations:
|
Each fiduciary of a pension, profit-sharing or other employee
benefit plan subject to Title I of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”) (a “Plan”),
should consider the fiduciary standards of ERISA in the context of the Plan’s particular circumstances before authorizing
an investment in the securities. Accordingly, among other factors, the fiduciary should consider whether the investment would satisfy
the prudence and diversification requirements of ERISA and would be consistent with the documents and instruments governing the
Plan.
In addition, we and certain of our affiliates, including MS &
Co., may each be considered a “party in interest” within the meaning of ERISA, or a “disqualified person”
within the meaning of the Internal Revenue Code of 1986, as amended (the “Code”), with respect to many Plans, as well
as many individual retirement accounts and Keogh plans (such accounts and plans, together with other plans, accounts and arrangements
subject to Section 4975 of the Code, also “Plans”). ERISA Section 406 and Code Section 4975 generally prohibit transactions
between Plans and parties in interest or disqualified persons. Prohibited transactions within the meaning of ERISA or the Code
would likely arise, for example, if the securities are acquired by or with the assets of a Plan with respect to which MS &
Co. or any of its affiliates is a service provider or other party in interest, unless the securities are acquired pursuant to an
exemption from the “prohibited transaction” rules. A violation of these “prohibited transaction” rules
could result in an excise tax or other liabilities under ERISA and/or Section 4975 of the Code for those persons, unless exemptive
relief is available under an applicable statutory or administrative exemption.
The U.S. Department of Labor has issued five prohibited transaction
class exemptions (“PTCEs”) that may provide exemptive relief for direct or indirect prohibited transactions resulting
from the purchase or holding of the securities. Those class exemptions are PTCE 96-23 (for certain transactions determined by in-house
asset managers), PTCE 95-60 (for certain transactions involving insurance company general accounts), PTCE 91-38 (for certain transactions
involving bank collective investment funds), PTCE 90-1 (for certain transactions involving insurance company separate accounts)
and PTCE 84-14 (for certain transactions determined by independent qualified professional asset managers). In addition, ERISA Section
408(b)(17) and Code Section 4975(d)(20) provide an exemption for the purchase and sale of securities and the related lending transactions,
provided that neither the issuer of the securities nor any of its affiliates has or exercises any discretionary authority or control
or renders any investment advice with respect to the assets of the Plan involved in the transaction and provided further that the
Plan pays no more, and receives no less, than “adequate consideration” in connection with the transaction (the so-called
“service provider” exemption). There can be no assurance that any of these class or statutory exemptions will be available
with respect to transactions involving the securities.
Because we may be considered a party in interest with
respect to many Plans, the securities may not be purchased, held or disposed of by any Plan, any entity whose underlying assets
include “plan assets” by reason of any Plan’s investment in the entity (a “Plan Asset Entity”) or
any person investing “plan assets” of any Plan, unless such purchase, holding or disposition is eligible for exemptive
relief, including relief available under PTCEs 96-23, 95-60, 91-38, 90-1, 84-14 or the service provider exemption or such purchase,
holding or disposition is otherwise not prohibited. Any purchaser, including any fiduciary purchasing on behalf of a Plan, transferee
or holder of the securities will be deemed to have represented, in its corporate and its fiduciary capacity, by its purchase and
holding of the securities that either (a) it is not a Plan or a Plan Asset Entity and is not purchasing such securities on behalf
of or with “plan assets” of any Plan or with any assets of a governmental, non-U.S. or church plan that is subject
to any federal,
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
|
state, local or non-U.S. law that is substantially similar to
the provisions of Section 406 of ERISA or Section 4975 of the Code (“Similar Law”) or (b) its purchase, holding and
disposition of these securities will not constitute or result in a non-exempt prohibited transaction under Section 406 of ERISA
or Section 4975 of the Code or violate any Similar Law.
Due to the complexity of these rules and the penalties that may
be imposed upon persons involved in non-exempt prohibited transactions, it is particularly important that fiduciaries or other
persons considering purchasing the securities on behalf of or with “plan assets” of any Plan consult with their counsel
regarding the availability of exemptive relief.
The securities are contractual financial instruments. The financial
exposure provided by the securities is not a substitute or proxy for, and is not intended as a substitute or proxy for, individualized
investment management or advice for the benefit of any purchaser or holder of the securities. The securities have not been designed
and will not be administered in a manner intended to reflect the individualized needs and objectives of any purchaser or holder
of the securities.
Each purchaser or holder of any securities acknowledges and agrees
that:
(i) the
purchaser or holder or its fiduciary has made and shall make all investment decisions for the purchaser or holder and the purchaser
or holder has not relied and shall not rely in any way upon us or our affiliates to act as a fiduciary or adviser of the purchaser
or holder with respect to (A) the design and terms of the securities, (B) the purchaser or holder’s investment in the securities,
or (C) the exercise of or failure to exercise any rights we have under or with respect to the securities;
(ii) we
and our affiliates have acted and will act solely for our own account in connection with (A) all transactions relating to the
securities and (B) all hedging transactions in connection with our obligations under the securities;
(iii) any
and all assets and positions relating to hedging transactions by us or our affiliates are assets and positions of those entities
and are not assets and positions held for the benefit of the purchaser or holder;
(iv) our
interests are adverse to the interests of the purchaser or holder; and
(v) neither
we nor any of our affiliates is a fiduciary or adviser of the purchaser or holder in connection with any such assets, positions
or transactions, and any information that we or any of our affiliates may provide is not intended to be impartial investment advice.
Each purchaser and holder of the securities has exclusive responsibility
for ensuring that its purchase, holding and disposition of the securities do not violate the prohibited transaction rules of ERISA
or the Code or any Similar Law. The sale of any securities to any Plan or plan subject to Similar Law is in no respect a representation
by us or any of our affiliates or representatives that such an investment meets all relevant legal requirements with respect to
investments by plans generally or any particular plan, or that such an investment is appropriate for plans generally or any particular
plan. In this regard, neither this discussion nor anything provided in this document is or is intended to be investment advice
directed at any potential Plan purchaser or at Plan purchasers generally and such purchasers of these securities should consult
and rely on their own counsel and advisers as to whether an investment in these securities is suitable.
However, individual retirement accounts, individual
retirement annuities and Keogh plans, as well as employee benefit plans that permit participants to direct the investment of their
accounts, will not be permitted to purchase or hold the securities if the account, plan or annuity is for the benefit of an employee
of Morgan Stanley or Morgan Stanley Wealth Management or a family member and the employee receives any compensation (such as,
for example, an addition to bonus) based on the purchase of the securities by the account, plan or annuity.
|
Additional considerations:
|
Client accounts over which Morgan Stanley, Morgan Stanley Wealth Management or any of their respective subsidiaries have investment discretion are not permitted to purchase the securities, either directly or indirectly.
|
Supplemental information regarding
plan of distribution; conflicts of interest:
|
Selected dealers, which may include our affiliates,
and their financial advisors will collectively receive from the agent a fixed sales commission of $ for each security they sell.
MS & Co. is an affiliate of MSFL and a wholly owned
subsidiary of Morgan Stanley, and it and other affiliates of ours expect to make a profit by selling, structuring and, when applicable,
hedging the securities. When MS & Co. prices this offering of securities, it will determine the economic terms of the securities,
including the contingent monthly coupon rate, such that for each security the estimated value on the pricing date will be no lower
than the minimum level described in “Investment Summary” beginning on page 4.
MS & Co. will conduct this offering in compliance
with the requirements of FINRA Rule 5121 of the Financial Industry Regulatory Authority, Inc., which is commonly referred to as
FINRA, regarding a FINRA member firm’s distribution of the securities of an affiliate and related conflicts of interest.
MS & Co. or any of our other affiliates may not make sales in this offering to any
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due September 30, 2024, With 1.5-year Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR® S&P® Biotech ETF and the Energy Select Sector SPDR® Fund
|
discretionary account. See “Plan of Distribution (Conflicts of Interest)” and “Use of Proceeds and Hedging” in the accompanying product supplement for auto-callable securities.
|
Where
you can find more information:
|
Morgan Stanley and MSFL have filed a registration statement (including
a prospectus, as supplemented by the product supplement for auto-callable securities and the index supplement) with the Securities
and Exchange Commission, or SEC, for the offering to which this communication relates. You should read the prospectus in that registration
statement, the product supplement for auto-callable securities, the index supplement and any other documents relating to this offering
that MSFL and Morgan Stanley have filed with the SEC for more complete information about Morgan Stanley and this offering. You
may get these documents without cost by visiting EDGAR on the SEC web site at.www.sec.gov. Alternatively,
MSFL, Morgan Stanley, any underwriter or any dealer participating in the offering will arrange to send you the prospectus and the
product supplement for auto-callable securities and the index supplement if you so request by calling toll-free 1-(800)-584-6837.
You may access these documents on the SEC web site at.www.sec.gov
as follows:
Product Supplement for Auto-Callable Securities dated November 16, 2017
Index Supplement dated November 16, 2017
Prospectus dated November 16, 2017
Terms used but not defined in this document are defined
in the product supplement for auto-callable securities, the index supplement or in the prospectus.
|
Morgan Stanley Depository Shares Representing 1/1000TH Preferred Series 1 Fixed TO Floating Non (Cum) (NYSE:MSPI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Morgan Stanley Depository Shares Representing 1/1000TH Preferred Series 1 Fixed TO Floating Non (Cum) (NYSE:MSPI)
Historical Stock Chart
From Jul 2023 to Jul 2024